Leerink Partners Resumes Kura Oncology (KURA) at Outperform; Data Rich 2017

October 13, 2016 6:38 AM EDT
Get Alerts KURA Hot Sheet
Price: $5.45 +4.81%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade KURA Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners resumes coverage on Kura Oncology (NASDAQ: KURA) with a Outperform rating and a price target of $15, citing attractive risk/reward ahead of a data rich 2017.

Analyst Jonathan Chang commented, "We are resuming coverage of Kura Oncology (KURA) with an Outperform (OP) rating and a $15 price target (PT). We view KURA's lead pipeline program, tipifarnib (a farnesyltransferase inhibitor) as a safe and active drug. KURA licensed worldwide rights to tipifarnib in oncology from Janssen (JNJ [OP]), which previously evaluated tipifarnib broadly across various hematologic and solid tumors with limited success. We believe KURA's precision medicine approach to developing tipifarnib in biomarker-defined patients offers the opportunity to improve on past efforts."

For an analyst ratings summary and ratings history on Kura Oncology click here. For more ratings news on Kura Oncology click here.

Shares of Kura Oncology closed at $5.60 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Add Your Comment